Stockreport

Aviragen completes enrollment in mid-stage study of teslexivir in condyloma; shares ahead 8% premarket [Seeking Alpha]

Atea Pharmaceuticals, Inc. - common stock  (AVIR) 
PDF Aviragen completes enrollment in mid-stage study of teslexivir in condyloma; shares ahead 8% premarketThinly traded nano cap Aviragen Therapeutics (NASDAQ:AVIR) is up8% [Read more]